SAGE
Companies
NASDAQ
Sage Therapeutics Inc.
Health Care
$9.13
+$3.70 (+68.14%)
Price Chart
Overview
About SAGE
Sage Therapeutics Inc is a clinical-stage biopharmaceutical company focused on brain health medicines. The company is targeting diseases and disorders of the brain with three key focus areas: depression, neurology and neuropsychiatry; also targeting two critical central nervous system, or CNS, receptor systems, GABA and NMDA. Its products ZURZUVAE is a medicine for the treatment of postpartum depression, or PPD, in adults, and ZULRESSO is a CIV injection for the treatment of postpartum depression in individuals 15 years old and older. It also has other drugs in its pipeline such as SAGE-324, Dalzanemdor (SAGE-718) among others.
Market Cap
$636.7M
Volume
14.4M
Avg. Volume
12.3M
P/E Ratio
-1.532374
Dividend Yield
0.00%
Employees
633.0
Company Information
Risk & Correlation Analysis
Market Correlation
1.95
High Correlation
Volatility
High (0.76)
Relative to market
Macro Factor Sensitivities
Interest Rates
Low Sensitivity
Inflation
Low Sensitivity
GDP Growth
Low Sensitivity
Liquidity
Low Sensitivity
Commodity Prices
Low Sensitivity
Credit Quality
High Sensitivity
Portfolio Impact
Forecasts & Predictions
1-Month Target
$XXX.XX
+X.X% Potential
3-Month Target
$XXX.XX
+X.X% Potential
12-Month Target
$XXX.XX
+X.X% Potential
Technical Analysis
Based on technical indicators and chart patterns, SAGE shows...
AI Sentiment Analysis
Market sentiment analysis indicates...
Key Statistics
Market Cap$636.7M
Volume14.4M
P/E Ratio-1.53
Dividend Yield0.00%
Important Dates
Next Dividend
Next Earnings
February 12, 2025Related Securities
Pricing info last updated June 18, 2025 (after market close)Other info last updated April 2, 2025